Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles

A. Gallud; D. Warther; M. Maynadier; M. Sefta; F. Poyer; C. D. Thomas; C. Rouxel; O. Mongin; M. Blanchard-Desce; A. Morère; L. Raehm; P. Maillard; J. O. Durand; M. Garcia; M. Gary-Bobo

doi:10.1039/C5RA14640B

Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles†

A. Gallud,^a D. Warther,^b M. Maynadier,^c M. Sefta,^d F. Poyer,^efg C. D. Thomas,^efg C. Rouxel,^h O. Mongin,ⁱ M. Blanchard-Desce,^jg A. Morère,^a L. Raehm,^b P. Maillard,*^efg J. O. Durand,*^bg M. Garcia^a and M. Gary-Bobo*^a

Author affiliations

* Corresponding authors

^a Institut des Biomolécules Max Mousseron de Montpellier, UMR 5247 CNRS-Université Montpellier-ENSCM, Bâtiment (E), Faculté de Pharmacie, 15 avenue Charles Flahault BP14491, 34093 Montpellier, France
E-mail: magali.gary-bobo@inserm.fr

^b Institut Charles Gerhardt Montpellier, UMR5253, CNRS-UM2-ENSCM-UM1, CC1701 Place Eugène Bataillon, 34095 Montpellier Cedex 05, France
E-mail: durand@univ-montp2.fr

^c NanoMedSyn, 15, avenue Charles Flahault BP14491, 34093 Montpellier, France

^d Institut Curie, UMR144, Hôpital, 26 rue d'Ulm, 75248 Paris Cedex 05, France

^e Institut Curie, Research Center, PSL Research University, Chemistry, Modelisation and Imaging for Biology (CMIB), Bât 110-112, Centre Universitaire, F-91405 Orsay, France

^f CNRS UMR 9187, INSERM U 1196, Université Paris-Saclay Université Paris Sud 11, Bât 110-112, Centre Universitaire, Rue Henri Becquerel, F-91405 Orsay Cedex, France
E-mail: philippe.maillard@curie.fr

^g CNRS GDR 3049 PHOTOMED, UMR5623, Université Paul Sabatier, F 31062 Toulouse, France

^h Chimie et Photonique Moléculaires, CNRS UMR6510, Campus de Beaulieu, Université Rennes 1, 35042 Rennes, France

ⁱ Institut des Sciences Chimiques de Rennes (CNRS, UMR 6226), Université de Rennes 1, F-35042 Rennes Cedex, France

^j Université de Bordeaux, ISM, UMR 5255 CNRS, F-33400 Talence, France

Abstract

Research in nanomedicine has grown rapidly over the past few years and is playing a key role in the development of effective treatments for ophthalmological purpose. Retinoblastoma is an intraocular tumor triggered by genetic mutation in young children and photodynamic therapy (PDT) is currently developed as a promising non-mutagenic approach to treat this cancer. In this work, we have first identified two receptors, MRC2 and CD209, which are highly expressed by retinoblastoma. Then, we developed mesoporous silica nanoparticles (MSN) grafted with the antibodies anti-MRC2 and/or anti-CD209 for retinoblastoma PDT and imaging.

RSC Advances

Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles†

Abstract

Supplementary files

Article information

Download Citation

Author version available

Permissions

Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles

Social activity

Search articles by author

Spotlight

Advertisements